Aloe Vera for Type 2 Diabetes

Verdict: Possibly helps, but evidence is disputed

Pooled trials suggest oral aloe vera modestly lowers HbA1c and fasting glucose in type 2 diabetes and prediabetes, but the evidence rests on small, low-quality studies and is contradicted by major clinical guidelines, so it cannot be recommended as a treatment.

B 🟡 B Preliminary Evidence Disputed

🔬Why this grade7-layer evidence engine

Four pooled analyses point the same way, which is what earns a Preliminary (B) grade. Three meta-analyses (PMID 27009750, n=470; PMID 27152917, n=283; PMID 27347994, n=415) and one umbrella review (PMID 34563809) consistently found oral aloe vera lowered HbA1c by roughly 0.4% to 1.05%, with the largest effect in poorly-controlled patients. That cross-study agreement is a genuine signal rather than noise.

The grade is Disputed because that signal is fragile. Every underlying trial is small and low-quality, the aloe preparations and doses were never standardized, heterogeneity was high, and several author teams called their own results inconclusive (PMID 27347994). One meta-analysis statistically detected publication bias for fasting-glucose results (PMID 27152917, p=0.010), and in established diabetes the fasting-glucose effect was only borderline (PMID 27009750, p=0.05). No large, rigorous trial exists.

Authorities lean cautious to negative. The American Diabetes Association does not recommend aloe vera for glycemic benefit, and Mayo Clinic warns it can cause hypoglycemia when combined with diabetes medicines. On safety, the US FDA found aloe stimulant-laxative ingredients not generally recognized as safe and effective, and the WHO's IARC classifies aloe whole-leaf extract as possibly carcinogenic (Group 2B). Treat it as an unproven adjunct, not a substitute for established care.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.56
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Disputed
Confidence
70%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.34
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.70
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.557
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Effect of Aloe vera on glycaemic control in prediabetes and type 2 diabetes: a systematic review and meta-analysis
PMID: 27009750 2016 統合分析 n = 470
Finding: In type 2 diabetes, aloe vera produced a marginal FPG reduction (MD -1.17 mmol/L, 95% CI -2.35 to 0.00, p=0.05) and a significant HbA1c reduction (MD -11 mmol/mol, 95% CI -19 to -2, p=0.01). In prediabetes, FPG fell significantly (MD -0.22 mmol/L, 95% CI -0.32 to -0.12, p<0.0001) but HbA1c did not (MD -2 mmol/mol, 95% CI -5 to 1).
🟠 Limited quality Effect size: T2DM: HbA1c -11 mmol/mol (~ -1.0%); FPG -1.17 mmol/L (NS at p=0.05). Prediabetes: FPG -0.22 mmol/L; HbA1c NS
View on PubMed
Reduction of Fasting Blood Glucose and Hemoglobin A1c Using Oral Aloe Vera: A Meta-Analysis
PMID: 27152917 2016 統合分析 n = 283
Finding: Oral aloe vera significantly reduced FBG by 46.6 mg/dL (p<0.0001) and HbA1c by 1.05% (p=0.004). Subgroup with baseline FBG >=200 mg/dL showed a larger FBG reduction of 109.9 mg/dL (p<=0.0001). Publication bias was detected for FBG (p=0.010) but not HbA1c (p=0.602).
🟠 Limited quality Effect size: FBG -46.6 mg/dL; HbA1c -1.05%
View on PubMed
Efficacy of Aloe Vera Supplementation on Prediabetes and Early Non-Treated Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
PMID: 27347994 2016 統合分析 n = 415
Finding: Aloe vera significantly reduced FBG (MD -30.05 mg/dL, 95% CI -54.87 to -5.23, p=0.02) and HbA1c (MD -0.41%, 95% CI -0.55 to -0.27, p<0.00001). It also lowered triglycerides (p=0.0001), total cholesterol (p<0.00001) and LDL-C (p<0.00001), and raised HDL-C (p=0.04). Authors call the results inconclusive given limited trial quality.
🟠 Limited quality Effect size: FBG -30.05 mg/dL; HbA1c -0.41%
View on PubMed
Effectiveness of aloe vera in patients with type 2 Diabetes Mellitus and pre-diabetes: An overview of systematic reviews
PMID: 34563809 2021 Umbrella Review
Finding: Across 4 systematic reviews, in type 2 diabetes FBG decreased significantly (p<0.001) and HbA1c fell by approximately 0.95% (p=0.02); in prediabetes FBG improved (p=0.02), HbA1c fell ~0.31% (p=0.02), and triglycerides dropped ~5 mg/dL (p<0.001). Authors rated the body of evidence as moderate-to-high quality in favor of an effect.
🟠 Limited quality Effect size: T2DM: HbA1c ~ -0.95%; Prediabetes: HbA1c ~ -0.31%
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Against
The stimulant laxative ingredients aloe (including aloe extract and aloe flower extract) and cascara sagrada (including casanthranol, cascara fluidextract aromatic, cascara sagrada bark, cascara sagrada extract, and cascara sagrada fluidextract) in OTC drug products are not generally recognized as safe and effective or are misbranded. source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Cautious
費拉蘆薈(Aloe vera)及好望角蘆薈(A. ferox)品種的葉子,須確實完全去皮後,才能加工使用,且蘆薈素(aloin)的含量不可以超過10 ppm。使用蘆薈葉作為原料之食品必須標示「孕婦忌食」警語字樣;產品檢具經檢驗機構檢驗所含「蘆薈素」含量低於1 ppm之分析證明者,得免標前述之警語。 source↗
L4e WHO
Cautious
Aloe whole leaf extract is possibly carcinogenic to humans (Group 2B). [IARC Monographs Vol. 108, 2016 — sufficient evidence of carcinogenicity in experimental animals, inadequate evidence in humans] source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Taking aloe gel by mouth while taking diabetes medicines might raise the risk of low blood sugar, called hypoglycemia. source↗
L5c Cleveland Clinic
Neutral
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-type2-diabetes-INT-aloe-vera-001 繁體中文版 →